Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jacob J. Clement.
Biochemical and Biophysical Research Communications | 1991
Hing L. Sham; David A. Betebenner; Norman E. Wideburg; Ayda Saldivar; William E. Kohlbrenner; Sudthida Vasavanonda; Dale J. Kempf; Daniel W. Norbeck; Chen Zhao; Jacob J. Clement; John E. Erickson; Jacob J. Plattner
A series of novel difluoroketones with low molecular weight (less than 600 m.u.) and which are potent inhibitors of the HIV-1 protease (IC50 = 1.0 to 21 nM) were synthesized. These compounds also exhibited antiviral activity by inhibition of the cytopathic effect of HIV-1(3)B in MT-4 cells in vitro.
Antiviral Research | 1994
Jeffrey Alder; Michael J. Mitten; Dan Norbeck; Kennan Marsh; Earl R. Kern; Jacob J. Clement
A-73209 is a novel oxetanocin derivative with potent in vitro and in vivo activity against VZV, HSV-1, and HSV-2. A-73209 was two logs more potent than acyclovir against five thymidine kinase positive (TK+) strains of VZV in vitro (mean EC50 0.01 vs. 1.22 micrograms/ml). The activity of A-73209 was one log more potent than acyclovir against TK+ HSV-1 strains in vitro (EC50 = 0.03 vs. 0.32 micrograms/ml). A-73209 yielded a mean EC50 of 2.2 micrograms/ml compared to a mean EC50 of 0.37 micrograms/ml for acyclovir against a panel of TK+ HSV-2 strains in vitro. The in vitro activity of A-73209 against thymidine kinase negative or deficient strains of VZV, HSV-1 and HSV-2 was much lower than for the corresponding TK+ strains. A-73209 produced efficacy superior to acyclovir against lethal systemic or intracerebral HSV-1 infections in mice. The greater efficacy of A-73209 relative to acyclovir was especially apparent with oral dosing. Against HSV-2 infections in mice, the efficacy of A-73209 ranged from equal to 1.7 times less active relative to acyclovir with oral dosing. A-73209 was orally bioavailable in mice, with maximal serum concentrations well in excess of in vitro inhibitory concentrations. A-73209 appears to be a potent and selective agent against varicella-zoster virus and herpes simplex virus infections.
FEBS Letters | 1993
Hing L. Sham; David A. Betebenner; Norman E. Wideburg; Ayda Saldivar; William Kohlbrenner; Adrienne Craig-Kennard; Sudthida Vasavanonda; Dale J. Kempf; Jacob J. Clement; John E. Erickson; Jacob J. Plattner; Daniel W. Norbeck
A series of novel, pseudo‐symmetrical difluoroketones which are highly potent inhibitors of the HIV‐1 protease (IC50 = 1.55‐0.02 nM) were synthesized. These compounds also possess good antiviral activity by inhibition of the cytopathic effect of HIV‐13B in MT‐4 cells in vitro.
Journal of Medicinal Chemistry | 1990
Daniel W. Norbeck; Earl R. Kern; Seiji Hayashi; William Rosenbrook; Hing L. Sham; Thomas Herrin; Jacob J. Plattner; John W. Erickson; Jacob J. Clement; Robert N. Swanson; Nathan L. Shipkowitz; Dwight J. Hardy; Kennan Marsh; Gussie Arnett; William M. Shannon; Samuel Broder; Hiroaki Mitsuya
The Journal of Antibiotics | 1996
Gregory M. Brill; Warren M. Kati; Debra Montgomery; James P. Karwowski; Patrick E. Humphrey; Marianna Jackson; Jacob J. Clement; Sunil Kadam; Randal H. Chen; James B. McAlpine
Journal of Medicinal Chemistry | 1991
Larry L. Klein; Clinton M. Yeung; Daniel T. Chu; Edith McDonald; Jacob J. Clement; Jacob J. Plattner
The Journal of Antibiotics | 1992
Paul A. Lartey; Shari L. DeNinno; Ramin Faghih; Dwight J. Hardy; Jacob J. Clement; Jacob J. Plattner
The Journal of Antibiotics | 1996
Randal H. Chen; Shaun Tennant; David J. Frost; Michael J. O'Beirne; James P. Karwowski; Patrick E. Humphrey; Li Hong Malmberg; Won Choi; Kim Brandt; Paul West; Sunil Kadam; Jacob J. Clement; James B. McAlpine
Journal of Antimicrobial Chemotherapy | 1994
Jeffrey Alder; Michael J. Mitten; Nate Shipkowitz; Lisa E. Hernandez; Yu-hua Hui; Kennan Marsh; Jacob J. Clement
Canadian Journal of Chemistry | 1992
Daniel T. W. Chu; Akiyo Claiborne; Jacob J. Clement; Jacob J. Plattner